- Home
- Automated
- NDF A-Z listing
- Dabigatran Etexilate
D
Dabigatran Etexilate
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
Yes
Summary of Biologics
No
Active ingredient: Dabigatran
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Rivaroxaban 15 mg and 20 mg tablets, and apixaban 2.5 mg and 5 mg tablets for preventing stroke and systemic embolism in patients with NVAF and:
CHA2DS2-VASc score of 1 or more for men; and
CHA2DS2-VASc score of 2 or more for women.
Rivaroxaban or apixaban should not be used in patients with valvular AF (especially rheumatic mitral stenosis), or patients with prosthetic heart valves.
Subsidy status
[R] Rivaroxaban 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
[R] Apixaban 2.5 mg and 5 mg tablets are recommended for reclassification from MAF to the MOH Standard Drug List (SDL).
[NR] SDL subsidy or MAF assistance do not apply to any strengths of dabigatran.
The Ministry of Health’s Drug Advisory Committee has recommended:
Rivaroxaban 15 mg and 20 mg tablets, and apixaban 2.5 mg and 5 mg tablets for adults to:
treat deep vein thrombosis (DVT) and pulmonary embolism (PE); and
prevent recurrent DVT and PE.
Subsidy status
[R] Rivaroxaban 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.
[NR] MAF assistance do not apply to the following:
the use of rivaroxaban for isolated distal DVT; or
rivaroxaban 2.5 mg and 10 mg tablets.
[R] Apixaban 2.5 mg and 5 mg tablets are recommended for reclassification from MAF to the MOH Standard Drug List (SDL).
[NR] SDL subsidy or MAF assistance do not apply to any strengths of dabigatran.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Drug availability
Formulation | Public Healthcare Institution |
|---|---|
Capsule 75 mg |
|
Capsule 110 mg |
|
Capsule 150 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |